Article: VaxGen Begins Clinical Development of its Attenuated Smallpox Vaccine Candidate.

VaxGen, Inc. (VXGN.PK) announced today that it has initiated a Phase I/II clinical trial to evaluate the safety and immune response of its attenuated smallpox vaccine candidate, LC16m8. One of four clinical sites participating in this trial, University of Kentucky School of Medicine, will begin vaccinating volunteers today in the first clinical study of LC16m8 in the United States. Sponsored by VaxGen, the trial is expected to enroll approximately 150 people.

(LOGO: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO )

Saint Louis University Health Sciences Center, Stanford University and Vanderbilt University Medical Center are expected to begin ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!